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Streptococcus pneumoniae (pneumokokki) on yleisin bakteeripneumonian ja akuutin otiitin 
aiheuttaja lapsilla. Pneumokokki voi aiheuttaa myös vakavia invasiivisia infektioita kuten 
meningiittiä ja sepsistä. Eri tutkimuslähteiden mukaan 18-60 % pneumokokin aiheuttamista 
verenkiertoon levinneistä infektioista on kuitenkin piileviä, joilla ei ole vakavia tai tiettyyn elimeen 
paikannettavia oireita. Termillä pneumokokkemia tarkoitetaan juuri tällaista pneumokokin 
aiheuttamaa piilevää infektiota. 
 
Tämän tutkimuksen tarkoituksena oli selvittää veriviljelypositiivisten pneumokokkemiatapausten 
ilmaantuvuutta ja tunnusomaisia piirteitä verrattuna veriviljelypositiivisiin radiologisesti 
todennettuihin pneumokokkipneumoniatapauksiin. 
 
Tutkimusaineistona käytettiin vuosilta 2001-2010 retrospektiivisesti kerättyjä 105 lapsen 
potilastietoja. Laboratorion tietokannoista haettiin lapset, joiden veriviljelyssä kasvoi pneumokokki. 
vastasyntyneet, kirurgiset potilaat, lapset joilla oli vakava perussairaus, ja potilaat joilla todettiin 
invasiivinen fokus kuten meningiitti, jätettiin tutkimuksen ulkopuolelle. Kaikki tutkimuksessa 
mukana olleet lapset hoidettiin Tampereen yliopistollisen sairaalan lastentautien klinikassa ja 
asuivat sairaanhoitopiirin alueella. Pneumonia todettiin 38 potilaalla ja loppuja 67 potilasta 
käsiteltiin pneumokokkemiatapauksina. 
 
Pneumokokkemian vuosittainen ilmaantuvuus oli keskimäärin 2,48 /10 000 asukasta 1-12 
kuukauden, 4,96/10 000 13-24 kuukauden ja 1,86/10 000 2-4 vuoden ikäisillä lapsilla. Kaikki 
pneumokokkemiapotilaat olivat alle kuusivuotiaita. Pneumokokkemiatapauksissa sairaalaan tuloa 
edeltäneen kuumeilun ja toisaalta myös sairaalassa aloitetun suonensisäinen G-penisilliinihoidon 
kesto olivat lyhyempiä kuin pneumoniatapauksissa. Sairaalassa tulovaiheen veren leukosyyttiarvo 
oli suurempi pneumokokkemiapotilailla (keskiarvo 26,6 vs. 21,9 x10E9/L, p=0.012), mutta 
seerumin CRP-arvo oli suurempi pneumoniapotilailla (keskiarvo 160 vs. 37,4 mg/L, p < 0,001). 
Toisaalta pneumokokkemiapotilaiden CRP-arvo nousi merkittävästi ensimmäisten 
sairaalahoitopäivien aikana antibioottihoidosta ja kliinisestä toipumisesta huolimatta. Yleisimmät 
pneumokokin serotyypit olivat 6B ja 14, jotka aiheuttivat 53,2% pneumokokkemiatapauksista. 
 
Tämän tutkimuksen perusteella pneumokokkemialle tunnusomaisia piirteitä olivat alle kuuden 
vuoden ikä, nopea kuumeen nousu, korkea veren valkosolumäärä ja vain hieman kohonnut 
seerumin CRP-arvo sairaalaan tultaessa. 
 
Syyskuussa 2010 otettiin 10-valenttinen pneumokokkirokote (Synflorix®) kansalliseen 
rokotusohjelmaan. Tämä rokote olisi kattanut 82,3%  tutkimuksen pneumokokkemiatapauksista. 
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Abstract 
 
Aim. To evaluate the incidence and characteristics of blood culture-positive occult 
pneumococcemia compared with blood culture-positive pneumococcal pneumonia in children.  
Methods. In years 2001-2010, 105 children with positive blood cultures for Streptococcus 
pneumoniae were identified from hospital electronic files. The patient cards were retrospectively 
charted for clinical and laboratory data, and 38 patients had and 67 had not penumonia.  
Results. The annual incidence of pneumococcemia was, on average, 29.0/10,000 at 0-12 months, 
5.3/10,000 at 13-24 months and 1.9/10,000 at 2-4 years of ages, with no increasing or decreasing 
trend. The incidence of bacteremic pneumococcal pneumonia increased (p=0.022) during the study 
period.  The duration of fever before hospitalization (<24 hours 73.9% vs. 25.0%, p=0.022) and the 
duration of intravenous antibiotics, usually G-penicillin (median 72 vs. 96 hours, p=0.021) was 
shorter in pneumococcemia patients. On admission, blood leukocyte count was higher in 
pneumococcemia (mean 26.6 vs. 21.9 x10E9/L, p=0.012), but serum CRP was higher in pneumonia 
(median 160 vs. 67.4 mg/L, p<0.001). The serotypes 6B and 14 caused 53.2% of pneumococcemia 
cases.  
Conclusion. The incidence of pneumococcemia was highest in 1-to-2-year-old children, and typical 
for pneumococcemia was rapid onset of fever, high blood leukocyte count and a modestly elevated 
CRP on admission.  
 
Key notes. The incidence of pneumococcemia was highest in 1-2 years old children, with no 
increasing trend during the study period. Instead, the incidence of bacteremic pneumococcal 
pneumonia increased significantly.  Currently available 7-valent, 10-valent and 13-valent vaccines 
would have covered 77.4%, 82.3% and 90.3% of pneumococcemia cases, respectively.  
 
Keywords. Pneumococcemia, Pneumonia, Streptococcus pneumoniae, Children, Occult bacteremia 
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[Introduction] 
 
Streptococcus pneumoniae is the most common cause of bacterial pneumonia and otitis media in 
children (1-2). In addition, S. pneumoniae is able to cause blood stream infections and invasive 
infections like meningitis (4-7). In children, less than 5% of pneumococcal pneumonias are 
bacteremic with positive blood cultures (8, 9).  On the other hand, pneumonia has been present in a 
third of children with pneumococcal bacteremia (3, 5, 6). In different studies, 18-60% of the 
pneumococcal bloodstream infections in children have been occult bacteremias with no severe or 
localizing signs or symptoms (3, 5, 6). An alternative term to occult pneumococcal bacteremia is 
pneumococcemia. When blood cultures have been systemically studied in <36 months old infants 
with high fever, S. pneumoniae has grown in 1.0-2.5% before and in 0-0.5% after large-scale 
pneumococcal vaccinations of infants (7, 10, 11).  Blood leukocytes, especially neutrophils, have 
usually been substantially elevated but levels of other host markers like C-reactive protein (CRP) 
have varied (8, 11, 12). Clinical experience strongly suggests that there are a substantial number of 
patients with probable pneumococcemia presenting with high fever, elevated leukocytes and 
increasing CRP, in whom blood cultures remain as negative.  
 
The aim of this retrospective hospital chart review was to evaluate the occurrence and 
characteristics of blood culture-positive pneumococcemia compared with blood culture-positive 
pneumococcal pneumonia. The data were collected for 10 years before the start of universal 
pneumococcal vaccinations of Finnish infants.  
 
 
Subjects and methods 
 
Children with positive blood cultures for Streptococcus pneumoniae, who were <16 years old and  
were treated in the Department of Pediatrics, Tampere University Hospital (Tampere, Finland) in 
years 2001-2010 were identified from the electronic files of the Laboratory Center of the hospital. 
Newborns treated in the neonatal wards, including neonatal intensive care unit, children with 
malignant diseases treated in the hemato-oncologic ward and children with surgical diseases treated 
in the ward of child surgery were not included. In all, 121 cases were found, and among them, 16 
children were additionally excluded: 12 had pneumococcal meningitis, 1 had an underlying 
immunosuppressive illness and 3 were treated for pneumococcal sepsis in the intensive care unit. 
The remaining 105 patients formed the subjects of the present study.  
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Two blood culturing instruments were used during the study period, until 2007 BACTEC 9240 (BD 
Diagnostic Systems, Sparks, MD, USA) and from 2007 BacT/ALERT 3D (bioMerieux SA, Marcy 
L'Etoile, France). 
 
Serotyping of the S. pneumoniae strains found in blood cultures was performed in the 
pneumococcal reference laboratory (National Public Health Institute, Oulu, Finland) by 
counterimmunoelectrophoresis with pneumococcal antisera (Statens Serum Institut, Copenhagen, 
Denmark) and for neutral serogroup 7 and serotype 14 by latex agglutination, as described 
previously (13). The capsular reaction test Quellung was used as a confirmation method when 
needed.   
 
One of the authors (HK) reviewed retrospectively the hospital records of the patients. The collected 
data included patients' age, gender, underlying illness, duration of fever before admission and 
during the hospital stay, length of hospital stay, body temperature on admission, general condition 
on admission, chest radiographs, blood leukocytes and serum C-reactive protein (CRP) on 
admission and on day 1-2 of the hospital stay, the duration of antibiotic treatments and the names of 
antibiotics used.  
 
Chest radiograph had been studied in 94 (89.5%) cases, and 38 children (36.2% of all children; 
40.4% of those with chest radiographs available) with an infiltration interpreted as pneumonia by 
the radiologist were allocated into the group of bacteremic pneumonia. The 56 children with no 
pneumonia in the chest radiograph and those 12 from whom radiograph was not studied (no clinical 
suspicion on pneumonia), were allocated into the group on bacteremia without pneumonia. Thus 
there were 67 children with pneumococcal bacteremia with no pneumonia or another invasive 
focus, and these patients are called as pneumococcemia cases in the present study. 
 
Statistics 
 
The data were analyzed with PASW Statistics 18 for windows package. In the exploratory data 
analysis, all variables except blood leukocytes were non-normally distributed, and therefore, Mann-
Whitney U test was used for these continuous variables. T-test was used for blood leukocytes. In the 
analyses of categorized variables, Chi-square test and Fisher`s exact test were used as appropriate. 
Logistic regression was used when adjustment for age was indicated. Poisson binomial regression 
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was used to analyze the annual trends in the occurrence of pneumococcemia and bacterial 
pneumococcal pneumonia. 
 
 
Tampere University Hospital is the only hospital providing inpatient care for children in the area. At 
the end of the year 2008, the child population aged <15 years was 84314 meaning an average age 
cohort of 5270 children (The Official Statistics of Finland). The annual age-specific incidence of 
pneumococcemia was calculated based on these figures.  
 
Ethics 
 
Since only data from hospital records were applied, the study was done by the permission of the 
Chief Doctor of the Tampere University Hospital. 
 
Results 
 
As seen in Fig. 1,  the annual number of pneumococcemia cases varied between 3-10, and the 
number of pneumonia cases varied between 1-7 with an increasing trend (p=0.022). There were 59 
(56%) boys and 46 girls. As seen in Fig. 2, the pneumococcemia / pneumonia ratio decreased in 
relation to age (p=0.007). All pneumococcemia cases were in children <6 years of age, and 20.9% 
were <12 months, 62.7% <24 months and 94.0% <48 months old (Fig. 2). On average, the annual 
age-specific incidence of pneumococcemia was 2.9/10,000 at 0-12 months, 5.3/10,000 at 13-24 
months and 1.9/10,000 at 2-4 years of age. 
 
The children with pneumococcemia were significantly younger (median 18 months) than children 
with pneumonia (Table 1). The duration of fever before hospitalization was shorter in 
pneumococcemia than in pneumonia patients (<24 hours 73.9% vs. 25.0%; <48 hours 86.2% vs. 
61.1%; p=0.022). Likewise, the duration of intravenous antibiotics, usually penicillin G (median 
(IQR) 72 (48-96) vs. 96 (72-120) hours, p=0.021) was shorter in pneumococcemia patients. 
However, there were no significant differences in the duration of fever in hospital or in the length of 
hospital stay (Data not shown).  Two-thirds of the pneumococcemia patients became non-feverish 
within 12 hours in hospital, and all children recovered without any complications. 
 
On admission, blood leukocyte count was higher in children with pneumococcemia (mean 26.6 
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x10E9/L) than in children with pneumonia, but serum CRP was higher in children pneumonia 
(median 160 mg/L) (Table 1). Serum CRP was even low (<11.4 mg/L) in 25% of pneumococcemia 
patients. The difference in CRP between the groups remained statistically significant in logistic 
regression adjusted for age (p=0.019), but the difference in blood leukocytes changed to non-
significant (p=0.290). In pneumococcemia cases, serum CRP increased significantly during 1-2 
days in hospital, though intravenous antibiotics were started (Table 1).   
 
Over 70% of both pneumococcemia and pneumonia patients were treated primarily with 
intravenous G-penicillin, and both the start with and change to cephalosporins was rather rare 
(Table 2). The treatment continued with oral amoxicillin or penicillin in nearly all cases; 9.2% of 
pneumococcemia patients received cephalosporins, and 13.9% of pneumonia patients received 
cephalosporins or macrolides.    
 
Pneumococcal serotypes 6B and 14 were the two most common being present in 53.2% of 
pneumococcemia cases. Other 14 identified serotypes were seen in less than 10% each. There were 
no significant differences in serotype distribution between pneumococcemia and pneumonia 
patients (Table 3). Likewise, there were no significant differences between different years or 
between the four age groups (Data not shown). Currently available 7-valent, 10-valent and 13-
valent vaccines would have covered 77.4%, 82.3% and 90.3% of pneumococcemia cases, 
respectively. 
 
 
Discussion 
 
There are four main results in this retrospective, geographically representative, 10-year study on the 
occurrence and characteristics on blood culture-positive pneumococcemia vs. blood culture-positive 
pneumococcal pneumonia in children. First, pneumococcemia was more common than bacteremic 
pneumonia at <48 months of age, and all pneumococcemia cases were in children aged <6 years. 
Second, the duration of fever before admission was shorter in children with pneumococcemia, being 
less than 24 hours in over two-thirds.  Third, blood leukocytes on admission were higher in children 
with pneumococcemia, but it is important to note that on average, blood leukocytes were high, over 
20x10E9/L, in both groups. Instead, serum CRP was higher in children with bacteremic pneumonia 
on admission, but not anymore in hospital. Although intravenous antibiotics were introduced to all 
but one of pneumococcemia patients, serum CRP rose significantly during 1-2 days in hospital. And 
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fourth, the great majority of both pneumococcemia and pneumococcal pneumonia cases were 
treated with G-penicillin, and intravenous cephalosporins were used in <20% during hospitalization 
and oral cepahlosporins in <10% after hospitalization. 
 
In Finland, the average annual incidence of all invasive pneumococcal infections was 2.2/ 10,000 at 
age <12 months, 5.2/ 10,000 at age 12-24 months and 1.3/ 10,000 at age 25-48 months in 1995-
2002  (14), which fits well with our results. The present 5.3/ 10,000 incidence of pneumococcemia 
at 23-48 months of age was very similar to the 4.8/ 10,000 incidence in Spain (3). All these figures 
describe the situation before the start of universal pneumococcal vaccinations of infants and young 
children. The experience form other countries has shown that vaccinations are effective especially 
against the bacteremic forms of pneumococcal diseases, including occult pneumococcal bacteremia 
(10, 15, 16). In many countries, vaccinations against Haemophilus influenzae type b have totally 
eradicated invasive diseases (17), and S. pneumoniae has remained, regardless of the vaccination 
status of the area, the most frequent pathogen isolated from young children with blood stream 
infections (18, 19). 
 
The universal pneumococcal vaccinations of Finnish infants with 10-valent vaccine started in 
September 2010. Thus, about 1400 infants aged <1 year (27% of the age cohort) were vaccinated at 
least once in 2010 in the study area. In addition, 2300 infants aged <18 months (22% of the age 
cohort) had been vaccinated in the otitis media study in 2009 and 1700 infants (16% of the age 
cohort) in 2010. Concerning pneumococcemia, the years 2009 and 2010 were low-incidence years, 
as were also the years 2003, 2006 and 2008. We consider that these variations are within the rates of 
spontaneous annual variations and that our results well represent the situation before universal 
pneumocccal vaccinations of infants.  
 
In the present study, radiological infiltrations were seen in 36% of the patients with pneumococcal 
bacteremia. The pneumonia / pneumococcemia ratio sounds high, and may be due to pulmonary 
infiltrates caused by preceding or concomitant viral infection (8, 20).  On the other hand, this may 
also reflect the increase of pneumococcal pneumonia, as demonstrated in the present study and in 
many previous studies before universal pneumococcal vaccinations (21, 22).  In a Finnish, 
prospective, population-based study, age-, sex- and place of residence-specific incidence of 
serologically confirmed pneumococcal pneumonia varied between 48-188/ 10,000 in 0-4-year old 
children (23). Since 1-2% of pediatric pneumococcal pneumonias were blood culture-positive (23), 
the current incidence of bacteremic pneumococcal pneumonia, 1.6/ 10,000, is in line with 
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population-based incidence of overall pneumococcal pneumonia in young children. 
 
The clinical picture of pneumococcemia is poorly characterized, as reflected by the other name of 
the disease, occult pneumococcal bacteremia. Clinical experience suggests that the patients are <5 
years old, and present with rapid onset of high fever. The general condition is modestly but not 
severely decreased. Blood leukocytes and especially neutrophils are elevated, and serum CRP may 
be only slightly elevated, or even low (11, 12, 24) as seen in 25% of the present patients. Serum 
CRP reflects tissue damage and needs >8 hours to elevate in blood stream infections. In a study 
from Switzerland, clinical signs predictive for severe invasive pneumococcal disease in <5 years 
old children were tachycardia for sepsis, tachypnea for pneumonia, and meningeal signs for 
meningitis. Leukocyte, neutrophil and platelet counts were lower and CRP concentrations were 
higher on admission in children with complicated infection than in children with uncomplicated 
infection but, due to wide overlap, the tests were not of prognostic value (25). In two other studies, 
high blood leukocytes (>20.0 x10E9/L, likelihood ratio 7.1) and high blood neutrophils (>15.0 
x10E9/L, likelihood ratio 10.7) were both sensitive and specific to screen pneumococcemia among 
young feverish children (11, 12, 24, 26). In the present study, pneumococcemia was associated with 
higher blood leukocytes and lower serum CRP compared to bacteremic pneumonia on admission. 
Though children became non-feverish rapidly and improved well after starting antibiotics, serum 
CRP continued to increase the next two days in hospital.  
 
Antibiotic resistance in bacterial strains must be considered when selecting treatment for invasive or 
bacteremic pneumococcal infections. In Finland, <5% of S. pneumoniae strains are resistant to 
penicillin, and thus, penicillin is still the first-line drug in pneumococcal infections (27). 
Accordingly, the therapy was successfully started with intravenous G-penicillin in 80% and 
continued with oral penicillin or amoxicillin in 90% of both pneumococcemia and bacteremic 
pneumonia cases. 
 
The result that serotypes 6B and 14 were the two predominating serotypes is in accordance with 
earlier observations from Finland. In 1985-1989, the most common serogroups / types were, in this 
order, 14, 6, 19, 7, 18 and 23, and formed 78% of all invasive 452 pneumococcal infections in 
Finnish children (28). In 1995-2002, the most common serotypes in children under 5 years were 6B, 
14, 19A, 18C and 7F (14). Currently available 7-valent, 10-valent and 13-valent vaccines would 
have covered 77.4%, 82.3% and 90.3% of the pneumococcemia cases of the present study.  
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The results of the present study must be interpreted cautiously. This was a retrospective hospital 
chart review, though covering 10 years and a geographically defined child population. This means 
that in feverish children, blood bacterial cultures and chest radiographs were taken on clinical 
indications, and not systemically. Despite of these limits, the current study provides useful pre-
vaccination data on pneumococcal bacteremia for further post-vaccination studies. 
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Figure 1. Annual hospitalizations for pneumococcemia and bacteremic pneumococcal pneumonia 
in years 2001-2010 (p= 0.022 for the increasing trend of the incidence of bacteremic pneumococcal 
pneumonia)  
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Figure 2. Pneumococcemia and bacteremic pneumococcal pneumonia in relation to age (all 
pneumococcemia cases were in children <6 years of age) 
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Table 1. Age, sex, fever, general condition and laboratory markers on admission and during the two 
first days in the hospital in the relation of pneumococcemia vs. bacteremic pneumococcal 
pneumonia    
  
                                                    
Parameter Pneumococcemia group 
(N=67) 
p value Pneumonia group 
(N=38) 
Age in months 
(median, range) 
18 (1.2-67) 
 
0.005 28 (4.8-192) 
 
Males 38 (56.7%) 0.885 21 (55.3%) 
Females 29 (43.3%)  17 (44.7%) 
    
On admission    
Blood leukocytes 
x10E9/L (mean, SD) 
26.6  (8.3) 
 
0.012 21.9 (8.8) 
 
Serum C-reactive 
protein mg/L 
(median, IQR) 
67.4 (11.4-112.4) 
 
<0.001 160.0 (68.5-222.2) 
Body temperature 
°C (mean, SD) 
39.7 (0.52) 0.115 39.5 (0.82) 
General condition 
decreased  
16 (23.9%) 0.158 14 (36.8%) 
    
On day 1-2 in 
hospital 
   
Blood leukocytes 
x10E9/L (mean, SD) 
22.5 (9.3)1 0.805 21.6 (13.0)2 
Serum C-reactive 
protein mg/L 
(median, IQR) 
94.6 (53.9-154.2)3 0.733 110.3 (69.8-165.9)4 
SD = standard deviation; IQR = interquartile range 
p1 = 0.051 vs. on admission 
p2 = 0.0.114 vs. on admission 
p3 = <0.001 vs. on admission 
p4 = 0.691 vs. on admission 
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Table 2. Empirically selected intravenous antibiotics before blood culture results in the 
pneumococcemia or bacteremic pneumococcal pneumonia groups 
 
 
Intravenous antibiotics Pneumococcemia group 
(N=65) 
Pneumonia group  
(N=35) 
G-penicillin primarily 52 (80.0%) 28 (80.0%) 
Change to cefalosporin 8/50 (16.0%) 3/25 (12.0%) 
Cefuroxime primarily 5 (7.7%) 4 (11.4%) 
Total cefalosporins 14 (21.5%) 7 (20.0%) 
Five patients were not included in the table:  one patient in the pneumococcemia group received ceftriaxone; one in the 
pneumococcemia group and one  in the pneumonia group did not receive intravenous antibiotics; two in the pneumonia 
group received antibiotics in combinations. 
 
Table 3. Serotypes in pneumococcemia and bacteremic pneumococcal pneumonia patients 
 
Serotype All 
N=98  
Pneumococcemia 
N=62 
Bacteremic 
pneumonia 
N=36 
3 3 (3.1%) 1 2 
6A 2 (2.0%) 2 0 
6B 23 (23.5%) 171 6 
7F 8 (8.2%) 3 5 
9V 5 (5.1%) 3 22 
14 26 (26.5%) 16 10 
15B 1 (1.0%) 0 1 
15C 1 (1.0%) 1 0 
18C 7 (7.1%) 6 1 
19A 6 (6.1%) 2 4 
19F 5 (5.1%) 5 0 
22F 2 (2.0%) 0 2 
23A 2 (2.0%) 2 0 
23F 4 (4.1%) 2 2 
33 1 (1.0%) 1 0 
38 2 (2.0%) 1 1 
 
1: One patient had both serotype 6B and 6A 
2: One patient had both serotype 9V and 10 
